pharmaspecialist
29 Dec 2015
Re: 2016 Sorry kilindidni I haven't a clue where the share price will be in the New Year but I am sure if you hold for 5 years or more you won't be disappointed. This is one of my favourite shares.
kilindidni
29 Dec 2015
2016 Are we heading for a 700 sp in the New Year? The momentum in December amazed me because there seemed to be no special reason. Any ideas anyone? Am thinking of adding a few more to my ISA.
kilindidni
16 Dec 2015
Rise in sp. Why the increase in activity in the last two weeks or so? No news of any real interest. As far as I can judge and the market not lively in the same period. Another good day today...
LK Hyman
10 Oct 2015
T. Rowe Price TRP is the second biggest shareholder after Jonathan Milner and appears to be slowly reducing its stake. It's now just under 9%. I wonder if this is the reason for the latest slight weakness in the share price?LKH on the flybridge
Eating Grass
08 Aug 2015
Celebratory ditty Ditty to celebrate Abcam's amazing success with apologies for my poor poetic prowess.Antibodies work like a molecular key in a hopeto reveal mechanisms of life under the microscope.The clever bar codes integrated within Fireflygives researchers a unique miRNA profile spy.Abcam technological advances and tools appear;enabling scientists to explore the biological frontier.We experience direct financial benefit in our pocketas the biotechnology makes the bottom line rocket. Sales shipped now exceed 150,000 units over 90 days.(Source: Molly the sheep on the Abcam main web page).
LK Hyman
31 Jul 2015
Re: Sharp falls recently Quiet-man,I don't think we'll be seeing <<BANG-ON!>> from Lambo here any time soon, m8.LKH on the flybridge famous last words
quiet-man
31 Jul 2015
Re: Sharp falls recently sorry, the previous post was in response to lambrini girl
quiet-man
31 Jul 2015
Re: Sharp falls recently Think you need a new machine.....
Ytong
30 Jul 2015
Re: Sharp falls recently I know you do this by charting, but if you see such a big disparity between what you have predicted and that which transpires...can you ever rely on it?Please don't be affended it's probably that I don't really know enough about.
Eating Grass
27 Jul 2015
Strange rating by Canaccord Canaccord Genuity analysts appear to be populated by canards that is ducks - no surprise when they appear to be based in French Canada.Their latest advice has been to upgraded Abcam to "hold from sell". You can't make this up. They have seen the terrific performance "increase in core catalogue business by +16%" and so have daringly have bumped their price target to 500 pence a share from 467 pence.Wow - but the price is 580 today and climbing.What will the price be when analysts get around to properly rerating Abcam to reflect its prospects and PEG? I see the price easily exceeding 600. DYOR...
kilindidni
24 Jul 2015
Some movement at last Encouraging announcement, followed by striking rise in sp. I still hold the view that a move to a full Stockmarket Listing is in sight. The changes made in the back room advisers in the last year or so suggest something is brewing, IMHO.
LK Hyman
23 Jul 2015
Excellent trading update There's only one thing to say:[link] on the flybridge
Eating Grass
27 Jun 2015
Re: Are your genes switched on? True enough. Very difficult to know exactly what genes are doing and when. Sometimes a gene will switch on just briefly in response to a signal to cause cell division or differentiation. However I believe there is a role for a quick simple test to screen for "epigenetic markers". In medicine we often use tests that lack specificity. For example temperature may indicate infection. So it points to patients deserving of further investigation like chest Xray, blood cultures etc. The appeal of Firefly is the panel can be customized for myriads of applications and we are at an early stage in seeing the potential. Firefly can be used in many labs utilising standard flow cytometer equipment to enable rapid uptake. Abcam is encouraging scientific meetings all around the world. For those who cannot get physically to a meeting there are on-line "webinars". Just as I predicted there are now Firefly panels especially for Breast cancer, Lung cancer, Prostate cancer, Immunology and several more - see the Abcam website. Life is too short to do RNA-seq in the way you describe and the cost as you already admit is prohibitive. I think the recent weakness in Abcam share price is a buying opportunity.
LK Hyman
23 Jun 2015
Re: Are your genes switched on? EG/q-m,Hmmmmm. I don't understand a word of what either of you are saying, though it all sounds good solid scientific stuff and beats comments such as "we're all gonna be rich by next Tuesday cos the goats' entrails say so, innit?" I wonder if I'm wise to be investing in a company about which I comprehend the square root of sweet fa?I'll mebbe chust stick with my original reason for putting a small percentage of my shrunken wad here, namely that, if the directors of Treatt (my biggest shareholding by a country mile) want Jeff Iliffe, the FD of Abcam, as a Treatt NED, then mebbe I should show some faith in Abcam.Rereading the para above, it sounds like a completely cockamamy reason to invest in Abcam, but there you go.Ah well, a company with a lorra smart white-coated pointyheads in Cambridge England AND Cambridge Massachusetts must be worth a punt, surely?[link] on the flybridge holding fir
quiet-man
23 Jun 2015
Re: Are your genes switched on? Partly correct ..... the miRNA profiling will tell you which miRNA genes are active but it will not directly tell you about other genes such as protein coding genes (i.e. those that transcribe mRNA). RNA-seq is still the gold standard for this because it detects all transcripts but it requires reverse transcription, library preparation and massive parallel DNA sequeincing - in other words it's expensive!
